Remegen Receives $650 Million Upfront Payment from AbbVie for RC148 Exclusive Licensing Agreement

Stock News

Apr 15

Remegen (09995) announced that on January 12, 2026, the company entered into an exclusive licensing agreement with AbbVie for RC148, which took effect on March 10, 2026. Under the agreement, AbbVie will obtain exclusive rights to develop, manufacture, and commercialize RC148 outside Greater China. In return, Remegen will receive an upfront payment of $650 million and is eligible for up to $4.95 billion in additional development, regulatory, and commercial milestone payments, as well as tiered double-digit royalties on net sales outside Greater China. The board of directors is pleased to announce that the company has received the $650 million upfront payment from AbbVie (through its holding company) for the exclusive licensing agreement of RC148, a novel self-developed PD-1/VEGF bispecific antibody drug. The collaboration between the two parties is currently progressing smoothly.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1190335375"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1190335375\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1190335375?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-15 16:48","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1190335375","market":"sg","top_or_hot":-1,"title":"Remegen Receives $650 Million Upfront Payment from AbbVie for RC148 Exclusive Licensing Agreement","media":"Stock News","content":"<p>Remegen (09995) announced that on January 12, 2026, the company entered into an exclusive licensing agreement with AbbVie for RC148, which took effect on March 10, 2026. Under the agreement, AbbVie will obtain exclusive rights to develop, manufacture, and commercialize RC148 outside Greater China. In return, Remegen will receive an upfront payment of $650 million and is eligible for up to $4.95 billion in additional development, regulatory, and commercial milestone payments, as well as tiered double-digit royalties on net sales outside Greater China. The board of directors is pleased to announce that the company has received the $650 million upfront payment from AbbVie (through its holding company) for the exclusive licensing agreement of RC148, a novel self-developed PD-1/VEGF bispecific antibody drug. The collaboration between the two parties is currently progressing smoothly.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Remegen Receives $650 Million Upfront Payment from AbbVie for RC148 Exclusive Licensing Agreement</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRemegen Receives $650 Million Upfront Payment from AbbVie for RC148 Exclusive Licensing Agreement\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-04-15 16:48</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Remegen (09995) announced that on January 12, 2026, the company entered into an exclusive licensing agreement with AbbVie for RC148, which took effect on March 10, 2026. Under the agreement, AbbVie will obtain exclusive rights to develop, manufacture, and commercialize RC148 outside Greater China. In return, Remegen will receive an upfront payment of $650 million and is eligible for up to $4.95 billion in additional development, regulatory, and commercial milestone payments, as well as tiered double-digit royalties on net sales outside Greater China. The board of directors is pleased to announce that the company has received the $650 million upfront payment from AbbVie (through its holding company) for the exclusive licensing agreement of RC148, a novel self-developed PD-1/VEGF bispecific antibody drug. The collaboration between the two parties is currently progressing smoothly.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2488822045.USD","symbol_name":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","start_time":0,"source_url":"","article_id":"1190335375","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1190335375","pubTimestamp":1776242901,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Remegen (09995) announced that on January 12, 2026, the company entered into an exclusive licensing agreement with AbbVie for RC148, which took effect on March 10, 2026. Under the agreement, AbbVie...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"688331":"荣昌生物","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","09995":"荣昌生物","BK1161":"生物科技","LU1064130708.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"I\" (USD) ACC","LU2148510915.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"R\" (USD) ACC","BK1574":"生物医药B类股","LU1969619763.USD":"EASTSPRING INV CHINA A SHARES GROWTH \"A\" (USD) ACC","LU1064131003.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"A\" (USD) ACC","LU2328871848.SGD":"Eastspring Investments - China A Shares Growth AS SGD","BK1583":"高瓴概念","BK0239":"医药制造"},"translate_title":"Remegen从艾伯维获得6.5亿美元的RC148独家许可协议预付款","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688331":1,"09995":1},"content_text":"Remegen (09995) announced that on January 12, 2026, the company entered into an exclusive licensing agreement with AbbVie for RC148, which took effect on March 10, 2026. Under the agreement, AbbVie will obtain exclusive rights to develop, manufacture, and commercialize RC148 outside Greater China. In return, Remegen will receive an upfront payment of $650 million and is eligible for up to $4.95 billion in additional development, regulatory, and commercial milestone payments, as well as tiered double-digit royalties on net sales outside Greater China. The board of directors is pleased to announce that the company has received the $650 million upfront payment from AbbVie (through its holding company) for the exclusive licensing agreement of RC148, a novel self-developed PD-1/VEGF bispecific antibody drug. The collaboration between the two parties is currently progressing smoothly.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}